Top line decelerating.
+12.9% YoY versus +18.0% prior. 3y CAGR +15.4%.
+12.9%We use cookies
MainRatios uses cookies for essential site functions. With your consent, we also use analytics cookies including session replay sampling (PostHog, Google Analytics) and advertising cookies (Google AdSense). You can reject non-essential cookies, including the "sale" or sharing of personal information under CCPA, and you may withdraw consent at any time (GDPR). See our Privacy Policy for details.
Healthcare · Market Cap: $10.8B
Fundamentals as of 2026-03-31
All analysis on this page is for educational purposes only and does not constitute financial advice. Fair values are model-based estimates. Always do your own research.
The Question
Bottom line: BMRN is flagged as overvalued by the 1 legendary model, but earns a B sector grade (68/100) in Healthcare. Use the per-tab analysis to form your own view. Drill into the valuation breakdown and sector ranking for the full picture.
Concerns — BioMarin Pharmaceutical Inc.'s 4.3% ROE is below sector median.
Financial story
Concerns — BioMarin Pharmaceutical Inc.'s 4.3% ROE and 0.38 debt-to-equity warrant a closer look at the underlying business.
BMRN and SOLV differ on P/E, ROE, and revenue growth. See the full BMRN vs SOLV compare matrix.
Lynch evaluates BMRN against his respective frameworks. Per-model fair value and reasoning are in the valuation tab.
BMRN's P/E ratio is 38.9x. 5-year P/E history is in the financials tab.
Investor verdicts vary by methodology. Full breakdown by investor and signal is in the valuation tab.
BMRN's earnings calendar and history are tracked in the financials tab. Specific dates depend on company-published guidance.
BMRN is in the Healthcare sector. Sector ranking and peer comparison are in the sector tab.
How does BMRN compare?
See exactly where BMRN ranks
Sign in to unlock the full sector ranking — free.
Sign in to see the rankingBMRN sits at #7 in Healthcare with a B grade (68/100).